Mark Agulnik, MD

Professor of Clinical Medicine

Vice Chair for Faculty Development, Department of Medicine

Section Chief of Sarcomas & Melanoma

Is this your profile? Click to edit

Request an Appointment

Publications

Stereotactic radiosurgery for brain metastases from primary head and neck carcinomas: a retrospective analysis. J Neurooncol. 2017 Aug; 134(1):197-203.. View in PubMed
Olaratumab for advanced soft tissue sarcoma. Expert Rev Clin Pharmacol. 2017 Jul; 10(7):699-705.. View in PubMed
Targeted Therapy in Head and Neck Cancer: An Update on Current Clinical Developments in Epidermal Growth Factor Receptor-Targeted Therapy and Immunotherapies. Drugs. 2017 May; 77(8):843-857.. View in PubMed
NCCN Guidelines Insights: Bone Cancer, Version 2.2017. J Natl Compr Canc Netw. 2017 02; 15(2):155-167.. View in PubMed
Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials. Oncotarget. 2017 Jan 31; 8(5):8910-8920.. View in PubMed
A phase II study of tivozanib in patients with metastatic and nonresectable soft-tissue sarcomas. Ann Oncol. 2017 01 01; 28(1):121-127.. View in PubMed
PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma. J Clin Oncol. 2016 11 10; 34(32):3898-3905.. View in PubMed
Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma. Ann Oncol. 2016 10; 27(10):1855-60.. View in PubMed
Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet. 2016 Jul 30; 388(10043):488-97.. View in PubMed
Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour. Eur J Cancer. 2016 07; 61:94-101.. View in PubMed

Mark Agulnik, MD

Publications

Similar People